Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00162136 · ClinicalTrials.gov registry record · Phase 1
Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies.
A Phase 1 study, sponsored by R-Pharm.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT00162136 is a Phase 1 study that has completed, run by R-Pharm. The registered enrollment target is 35 participants.
The verdict
NCT00162136, a Phase 1 study, has completed, sponsored by R-Pharm.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the dose limiting toxicities, minimum tolerated dose and recommended dose for Phase II studies.
Interventions
- DRUG Ixabepilone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2005-09 |
| Est. Completion | 2008-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00162136
The ClinicalTrials.gov registry entry for NCT00162136 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is R-Pharm, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ixabepilone is the first listed.
NCT00162136 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00162136 about?
NCT00162136 is a clinical study titled "Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies.". The purpose of this study is to determine the dose limiting toxicities, minimum tolerated dose and recommended dose for Phase II studies.
What is the current status of trial NCT00162136?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2005-09. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00162136?
The interventions under investigation include: Ixabepilone (DRUG).
Who is sponsoring clinical trial NCT00162136?
This trial is sponsored by R-Pharm, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.